{
    "symbol": "RMTI",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-30 10:02:08",
    "content": "   Operator: Good morning, and welcome to Rockwell Medical's Fourth Quarter and Full-Year 2022 Results Conference Call and Webcast. Rockwell Medical's annual report on Form 10-K for the year ended December 31, 2022 was filed prior to this call and provides a full analysis of the company's business strategy, as well as the company's fourth quarter and full-year 2022 results. Good morning, everyone, and thank you for joining us today for Rockwell Medical's fourth quarter and full-year 2022 results conference call and webcast. For the full-year 2022, Rockwell generated $72.8 million in revenue exceeding our guidance, which represents a 17.6% increase when compared to the comparable period in 2021 and the highest full-year revenue to date for the company. During the fourth quarter of 2022, we entered into an amendment of our loan agreement accelerating the pay down of our debt with a $5 million prepayment of our existing loan leaving Rockwell Medical with $10 million of long-term debt as of December 31, 2022. For the three months ended December 31, 2022, Rockwell's net loss was 2.4 million or $0.20 per share, compared with a net loss of 8.9 million or $1.05 per share for the same period of 2021. For the year ended December 31, 2022, Rockwell's net loss was 18.7 million or $1.89 per share, compared with a net loss of 32.7 million or $3.83 per share in 2021. During the fourth quarter of 2022, we accelerated the pay down of our debt with the $5 million prepayment of our existing loan leaving Rockwell Medical with 10 million of long-term debt at December 31, 2022."
}